BR112021011495A8 - Preparação incluindo adjuvante para vacina - Google Patents

Preparação incluindo adjuvante para vacina

Info

Publication number
BR112021011495A8
BR112021011495A8 BR112021011495A BR112021011495A BR112021011495A8 BR 112021011495 A8 BR112021011495 A8 BR 112021011495A8 BR 112021011495 A BR112021011495 A BR 112021011495A BR 112021011495 A BR112021011495 A BR 112021011495A BR 112021011495 A8 BR112021011495 A8 BR 112021011495A8
Authority
BR
Brazil
Prior art keywords
vaccine adjuvant
amino
preparation
preparation including
including vaccine
Prior art date
Application number
BR112021011495A
Other languages
English (en)
Other versions
BR112021011495A2 (pt
Inventor
ONITA Maiko
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of BR112021011495A2 publication Critical patent/BR112021011495A2/pt
Publication of BR112021011495A8 publication Critical patent/BR112021011495A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PREPARAÇÃO INCLUINDO ADJUVANTE PARA VACINA. A presente invenção refere-se a uma composição que é útil como um adjuvante para vacina e tem excelente estabilidade de armazenagem e atividade imunoestimulante. É especificamente provida uma preparação liofilizada que tem alta estabilidade de armazenagem, a referida preparação contendo uma (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hidroxihexan-3-il]amino}-6-metilpirimidin-5-il)metil] benzil}(metil)amino]etil}-4,8,12,17,21,25-hexametilhexacosa-4,8,12,16, 20,24-hexaenamida, esqualano, um tensoativo hidrofílico, e um tenso-ativo oleofílico, e sendo caracterizada por conter um antioxidante à base de ácido ascórbico e um excipiente.
BR112021011495A 2018-12-26 2019-12-25 Preparação incluindo adjuvante para vacina BR112021011495A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-242614 2018-12-26
JP2018242614 2018-12-26
PCT/JP2019/050947 WO2020138217A1 (ja) 2018-12-26 2019-12-25 ワクチンアジュバントを含む製剤

Publications (2)

Publication Number Publication Date
BR112021011495A2 BR112021011495A2 (pt) 2021-08-31
BR112021011495A8 true BR112021011495A8 (pt) 2022-12-06

Family

ID=71128695

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011495A BR112021011495A8 (pt) 2018-12-26 2019-12-25 Preparação incluindo adjuvante para vacina

Country Status (14)

Country Link
US (1) US20220072126A1 (pt)
EP (1) EP3903810A4 (pt)
JP (1) JP7410883B2 (pt)
KR (1) KR20210107770A (pt)
CN (1) CN113194986A (pt)
AU (1) AU2019413182A1 (pt)
BR (1) BR112021011495A8 (pt)
CA (1) CA3121613A1 (pt)
EA (1) EA202191786A1 (pt)
IL (1) IL284249A (pt)
MX (1) MX2021007849A (pt)
PH (1) PH12021551359A1 (pt)
SG (1) SG11202105787QA (pt)
WO (1) WO2020138217A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230109998A1 (en) * 2020-03-27 2023-04-13 Path Malaria transmission-blocking vaccines
JP2023532738A (ja) * 2020-06-29 2023-07-31 ピーエイティエイチ 前赤内期マラリアワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999056776A2 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
JP2001151699A (ja) 1999-11-29 2001-06-05 Nippon Surfactant Kogyo Kk 動物用ワクチンのオイルアジュバント
KR101847848B1 (ko) 2011-03-11 2018-04-12 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 시트룰린을 함유하는 애주번트 조성물
CN108290845B (zh) * 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
CA3057813A1 (en) 2017-03-29 2018-10-04 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
JP7395461B2 (ja) * 2018-07-23 2023-12-11 国立感染症研究所長 インフルエンザワクチンを含む組成物

Also Published As

Publication number Publication date
JP7410883B2 (ja) 2024-01-10
EP3903810A4 (en) 2022-12-14
AU2019413182A1 (en) 2021-06-17
JPWO2020138217A1 (ja) 2021-11-11
IL284249A (en) 2021-08-31
KR20210107770A (ko) 2021-09-01
BR112021011495A2 (pt) 2021-08-31
SG11202105787QA (en) 2021-06-29
CN113194986A (zh) 2021-07-30
US20220072126A1 (en) 2022-03-10
PH12021551359A1 (en) 2021-11-22
EP3903810A1 (en) 2021-11-03
MX2021007849A (es) 2021-08-11
CA3121613A1 (en) 2020-07-02
WO2020138217A1 (ja) 2020-07-02
EA202191786A1 (ru) 2021-11-03

Similar Documents

Publication Publication Date Title
BR112021011495A8 (pt) Preparação incluindo adjuvante para vacina
AR055414A1 (es) Nuevas formulaciones solidas que contienen sulfonamidas
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
RU2009116923A (ru) Применение spicules spongilla в качестве устройства для дермабразии или средства обновления поверхностных слоев кожи
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
KR960703567A (ko) 약제학적 조성물(Pharmaceutical composition)
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
AR080294A1 (es) Composiciones dirigidas a mejorar la solubilidad y administracion de los compuestos activos de magnolia
FR2968950B1 (fr) Composition cosmetique comprenant un compose d'acide cucurbique
BR112017010689A2 (pt) ?composição, processo cosmético e uso cosmético da composição e de éster de ácido?
ES2525544T3 (es) Derivados de aminoalcanoles, método de obtención de aminoalcanoles y su uso
BR112012007842A2 (pt) um copolímero em bloco e composição de poliesteramida com terminação éster e usos dos mesmos
CO2022011392A2 (es) Vacuna contra hpv
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
AR069010A1 (es) Proceso de preparacion de una composicion vacunal que comprende al menos un antigeno y al menos un adyuvante y uso
AR054729A1 (es) Sistema de administracion
ATE430571T1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen
CO5560531A2 (es) Producto antitranspirante con dibencilideno sorbitol y elastomero en dimeticona
BR112015029976A2 (pt) formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
EA202092922A1 (ru) Фармацевтический состав с улучшенной растворимостью и биологической доступностью
AR056017A1 (es) Formulaciones de vacuna animal, metodo para preparar una formulacion de vacuna y componente estabilizador de vacuna
ES2540091T3 (es) Base concentrada para productos de detergente y productos para higiene y cuidado personal que comprende una combinación de al menos tres tensioactivos no etoxilados
MX362717B (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)